Literature DB >> 184040

Cell-mediated immunity to varicella-zoster virus demonstrated by viral inactivation with human leukocytes.

A A Gershon, S Steinberg, M Smith.   

Abstract

Cell-mediated immunity to varicella-zoster (V-Z) virus in persons immune to varicella has been demonstrated, using a tissue culture technique. Cell-mediated immunity was reflected by the ability of peripheral leukocytes (lymphocytes and monocytes) from human donors to inactivate V-Z virus. Leukocytes were stimulated by the addition of noninfectious V-Z antigen to cultures newly infected with V-Z virus. Several days leter, the V-Z virus in these cultures was titered. When leukocytes from donors immune to caricella were used, a significant decrease in V-Z titer, compared with controls, was noted. When leukocytes from donors susceptible to varicella were tested, no decrease in V-Z virus titer was found. A mixed population of lymphocytes and monocytes from immune donors was required to demonstrate inactivation of V-Z virus. The development of specific cell-mediated immunity to V-Z virus may play a role in termination of varicella and in prevention of second attacks of this disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184040      PMCID: PMC420798          DOI: 10.1128/iai.13.6.1549-1553.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  CRUDE TISSUE CULTURE ANTIGEN FOR DETERMINATION OF VARICELLA-ZOSTER COMPLEMENT FIXING ANTIBODY.

Authors:  P A BRUNELL; H L CASEY
Journal:  Public Health Rep       Date:  1964-09       Impact factor: 2.792

2.  Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster.

Authors:  P A Brunell; A A Gershon; S A Uduman; S Steinberg
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

Review 3.  Passive immunization against varicella-zoster infections and other modes of therapy.

Authors:  P A Brunell; A A Gershon
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

4.  Characterization of glass adherent human mononuclear cells.

Authors:  C A Koller; G W King; P E Hurtubise; A L Sagone; A F LoBuglio
Journal:  J Immunol       Date:  1973-11       Impact factor: 5.422

5.  Cell-mediated immunity to Varicella-Zoster antigen in acute Herpes zoster (shingles).

Authors:  A S Russell; R A Maini; M Bailey; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

6.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

7.  Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses.

Authors:  G W Jordan; T C Merigan
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

8.  Varicella zoster virus: interferon production and comparative interferon sensitivity in human cell cultures.

Authors:  R W Armstrong; T C Merigan
Journal:  J Gen Virol       Date:  1971-07       Impact factor: 3.891

9.  Seroepidemiologic survey of varicella: Value of specific fluorescent antibody test.

Authors:  A A Gershon; S Krugman
Journal:  Pediatrics       Date:  1975-12       Impact factor: 7.124

10.  Cellular immunity to herpes simplex virus mediated by interferon.

Authors:  D L Lodmell; A L Notkins
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  6 in total

1.  Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

2.  Cell-mediated immunity to varicella-zoster virus measured by virus inactivation: mechanism and blocking of the reaction by specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

3.  Use of bone marrow fibroblasts to prepare targets for an HLA restricted-cytotoxicity assay system.

Authors:  R A Bowden; L McGavren; A R Hayward; M J Levin
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

4.  Inhibition of varicella-zoster virus in vitro by human peripheral blood mononuclear cells.

Authors:  G P Rabalais; F E Berkowitz; A R Hayward; M J Levin
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

5.  Antibody-dependent cell-mediated cytotoxicity against varicella-zoster virus-infected targets.

Authors:  H Kamiya; S E Starr; A M Arbeter; S A Plotkin
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

6.  Inactivation of varicella zoster virus in vitro: effect of leukocytes and specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.